Cardiovascular disease and diabetes

Advances in Experimental Medicine and Biology

Volumn 771, Issue , 2013, Pages 219-228

  Mangiapane, Heather ^a  

^a NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FATTY ACID; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE PREDISPOSITION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FATTY ACID BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; WEIGHT GAIN; ANIMAL; ATHEROSCLEROSIS; DIABETIC ANGIOPATHY; INCIDENCE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ATHEROSCLEROSIS; DIABETIC ANGIOPATHIES; HUMANS; HYPERGLYCEMIA; INCIDENCE; SIGNAL TRANSDUCTION;

MLCS; MLOWN;

EID: 84874550616     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5441-0_17     Document Type: Article

References (35)

1. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham Study. Circulation 1979; 59:8-13.
2. Kannel WB, McGee DL. Diabetes and cardiovascular disease. Journal of the American Medical Association 1979; 241:2035-2038.
3. Laakso M, Lehto S. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. Atherosclerosis 1998; 137:S65-S73.
4. Turner RC, Millns H, Neil HA. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study. British Medical Journal 1998; 316:823-828.
5. Garcia MJ, McNamara PM, Gordon T et al. Morbidity and mortality in the Framingham population. Sixteen year follow-up study. Diabetes 1974; 23:105-111.
6. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure. Am J Cardiol 1974; 34:29-34.
7. Natali A, Vichi S, Landi P et al. Coronary atherosclerosis in type II diabetes: angiographic findings and clinical outcomes. Diabetologia 2000; 43:632-641.
8. De Fronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard lecture 2009. Diabetologia 2010; 53:1270-1287.
9. Galle J, Schneider R, Winner B et al. Glyc-oxidised LDL impair endothelial function more potently than oxidised LDL: role of enhanced oxidative stress. Atherosclerosis 1998; 138:65-77.
10. Sobal G, Menzel J, Sinzingen H. Why is glycated LDL more sensitive to oxidation than native LDL? A comparative study. Prostaglandins, Leukotrienes and Essential Fatty Acids 2000; 63:177-186.
11. Berliner JA, Navab M, Fogelman AM et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation and genetics. Circulation 1995; 91:2488-2496.
12. Steinberg D. Low density lipoprotein oxidation and its pathological significance. Journal of Biological Chemistry 1997; 272:20963-20966.
13. Lusis AJ. Atherosclerosis. Nature 2000; 407:233-241.
14. Tabit CE, Chung WB, Hamburg NM et al. Endothelial dysfunctionin diabetes mellitus: molecular mechanisms and clinical implications. Rev Endocr Metab Dis 2010; 11:61-74.
15. Consentino F, Hishikawa K, Katusic Z et al. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 1997; 96:25-28.
16. Hedrick CC, Thorpe SR, Fu MX et al. Glycation impairs high density lipoprotein function. Diabetologia 2000; 43:312-320.
17. Nishikawa T, Edelstein D, Du XL et al. Normalising mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404:787-790.
18. Gleissner CA, Galkina E, Nadler JL et al. Mechanisms by which diabetes increases cardiovascular disease. Drug Discov Today Dis Mech 2007; 4:131-140.
19. Gleissner CA, Sanders J, Nadler J et al. Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidaemia and atherosclerosis. Arterioscler Thromb Vase Biol 2008; 28:1137-1143.
20. Singh R, Barden A, Mori T et al. Advanced glycation end products: a review. Diabetologia 2001; 44:129-146.
21. Park L, Raman KG, Lee KL. Suppression of accelerated atherosclerosis by the soluble receptor for advanced glycation end products. Nature Medicine 1998; 4:1025-1031.
22. Samuel VT, Peterson KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. The Lancet 2010; 375:2267-2277.
23. Belfort R, Mandarino L, Kashyap S et al. Dose-response effect of elevated plasma free fatty acid on insulin signalling. Diabetes 2005; 54:1640-1648.
24. Kashyap SR, Roman LJ, Lamont J et al. Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. J Clin Endocrinol Metab 2005; 90:1100-1105.
25. Li H, Li H, Bao Y et al. Free fatty acids induce endothelial dysfunction and activate protein kinase C and nuclear factor-kappaB in rat aorta. Int J Cardiol 2010, doi:10.1016/j.icard.2010.07.019.
26. Nathan DM, Zinman B, Cleary PA et al. Modern-day clinical course of type 1 diabetes mellitus after 30 year's duration. Archives of Internal Medicine 2009; 169:1307-1316.
27. Marso SP, Kennedy KF, House JA et al. The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes and Vascular Disease Research 2010; 7:119-130.
28. c and associated risk factors. Cardiovascular Diabetology 2010; 9:45-58.
29. Chaggar PS, Shaw SM, Williams SG. Thiazolidinediones and heart failure. Diabetes and Vascular Research 2009; 6:146-152.
30. Lincoff AM, Wolski K, Nicholls SJ et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis of randomised trials. JAMA 2007; 298:1180-1188.
31. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129-1136.
32. Maher VMG. Coronary atherosclerosis stabilisation: an achievable goal. Atherosclerosis 1995; 118:S91-S101.
33. Williams KJ, Feig JE, Fisher EA. Rapid regression of atherosclerosis: insights from the clinical and experimental literature. Nature Clinical Practice Cardiovascular Medicine 2008; 5:91-102.
34. Zhao XQ, Yuan C, Hatsukami TS et al. Effects of prolonged lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI; a case-control study. Arterioscler Thromb Vase Biol 2001;21:1623-1629.
35. Cohen JC, Boerwinkle E, Mosley TH et al. Sequence variations in PCSK9, low LDL and protection against coronary heart disease. New Eng J Med 2006; 354:1264-1272.